EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Phenotypic Plasticity and Androgen Receptor Bypass Drive Cross-Resistance to Apalutamide in Castration-Resistant Prostate Cancer Cell Models

Iris Simon iD, Jose Manuel Sanchez-Manas iD, Sonia Perales, Gonzalo Martinez-Navajas, Jorge Ceron-Hernandez iD, Pedro J Real iD

International Journal of Molecular Sciences · 20.06.2025 · 26 (13) · 5939

DOI: 10.3390/ijms26135939 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 20.06.2025. Verfasst von Iris Simon und 5 weiteren Autor:innen. Beteiligte Einrichtung: Gene Regulation, Stem Cells and Development Group, GENyO, Pfizer-University of Granada-Andalusian Regional Government Centre for Genomics and Oncolog…. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Castration-Resistant, Thiohydantoins, Receptors, Androgen, Drug Resistance, Neoplasm. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Economy and Competitiveness, FEDER/Junta de Andalucia-Consejeria de Transformacion Economica, Industria, Conocimiento y Universidades, European Regional Development Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The treatment of choice for prostate cancer is androgen deprivation (ADT) and novel hormonal agents such as Abiraterone, Enzalutamide, or Apalutamide. Initially, this therapy is highly effective, but a significant challenge arises as most patients eventually develop resistance, resulting in castration-resistant prostate cancer (CRPC). Furthermore, the sequential use of these drugs can lead to cross-resistance, diminishing their efficacy. Tumor heterogeneity plays a pivotal role in the development of resistance to different treatments. This study utilized cellular models of CRPC to assess the response to Apalutamide when it was administered as a second- or third-line treatment. Functional and genetic analyses were conducted in various CRPC cell models exposed to Apalutamide. These analyses included real-time cell monitoring assays, flow cytometry, clonogenicity assays, and RT-qPCR. CRPC cell models were capable of continued proliferation, maintained cell cycle profiles similar to those of untreated cells, and retained their clonogenic potential. Cross-resistance to Apalutamide in models of ADT, ADT plus Enzalutamide, or Abiraterone resistance did not correlate with the expression levels of AR-V7 and AR-V9 variants. Gene expression analysis of resistant prostate cancer cell lines revealed that treatment with Apalutamide induced the emergence of more aggressive phenotypes, including cancer stem cells or neuroendocrine differentiation profiles. Most CRPC cell models developed cross-resistance to Apalutamide and were able to proliferate and retain their clonogenic capability. Apalutamide resistance was not linked to the expression of AR-V7 or AR-V9 variants but was instead associated to bypass of AR signaling pathway and the emergence of more aggressive expression profiles.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic Neoplasms, Castration-ResistantThiohydantoinsReceptors, AndrogenDrug Resistance, NeoplasmCell PlasticityMaleHumansCell Line, TumorBenzamidesNitrilesCell ProliferationPhenylthiohydantoinGene Expression Regulation, NeoplasticPhenotype

Stichwörter der Autor:innen

AbirateroneApalutamideEnzalutamideandrogen deprivation therapy (ADT)castration-resistant prostate cancer (CRPC)prostate cancer

Substanzen

apalutamideThiohydantoinsReceptors, AndrogenBenzamidesNitrilesenzalutamidePhenylthiohydantoinAR protein, human

Autor:innen und Institutionen

  • Gene Regulation, Stem Cells and Development Group, GENyO, Pfizer-University of Granada-Andalusian Regional Government Centre for Genomics and Oncological Research, Avenida de la Ilustracion 114, PTS Granada, 18016 Grana…
  • Department of Biochemistry and Molecular Biology I, Faculty of Science, University of Granada, Avenida Fuentenueva s/n, 18071 Granada, Spain.
  • Instituto de Investigación Biosanitaria ibs.GRANADA, 18012 Granada, Spain.
  • Liquid Biopsies and Cancer Interception Group, GENyO, Pfizer-University of Granada-Andalusian Regional Government Centre for Genomics and Oncological Research, Avenida de la Ilustracion 114, PTS Granada, 18016 Granada,…

ORCID-Profile: Iris Simon, Jose Manuel Sanchez-Manas, Jorge Ceron-Hernandez, Pedro J Real

Förderung

  • Ministry of Economy and Competitiveness
  • FEDER/Junta de Andalucia-Consejeria de Transformacion Economica, Industria, Conocimiento y Universidades
  • European Regional Development Fund
  • FEDER/Junta de Andalucia
  • University of Granada
  • ROLUCAN Association
  • Predoctoral Recruitment of Research Trainees-Predoctoral studen
  • Spanish Health Institute Carlos III

Zitieren

APA

Simon, I., Sanchez-Manas, J. M., Perales, S., Martinez-Navajas, G., Ceron-Hernandez, J., & Real, P. J. (2025). Phenotypic Plasticity and Androgen Receptor Bypass Drive Cross-Resistance to Apalutamide in Castration-Resistant Prostate Cancer Cell Models. International Journal of Molecular Sciences, 26(13), 5939. https://doi.org/10.3390/ijms26135939

Vancouver

Simon I, Sanchez-Manas JM, Perales S, Martinez-Navajas G, Ceron-Hernandez J, Real PJ. Phenotypic Plasticity and Androgen Receptor Bypass Drive Cross-Resistance to Apalutamide in Castration-Resistant Prostate Cancer Cell Models. International Journal of Molecular Sciences. 2025;26(13):5939. doi:10.3390/ijms26135939

BibTeX
@article{Simon2025,
  author = {Simon, Iris and Sanchez-Manas, Jose Manuel and Perales, Sonia and Martinez-Navajas, Gonzalo and Ceron-Hernandez, Jorge and Real, Pedro J},
  title = {Phenotypic Plasticity and Androgen Receptor Bypass Drive Cross-Resistance to Apalutamide in Castration-Resistant Prostate Cancer Cell Models},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  volume = {26},
  number = {13},
  pages = {5939},
  doi = {10.3390/ijms26135939}
}
Kostenlos starten →